Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 14/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 12/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20647628 | 0.89 | HDAC6 (0.49) | HDAC6OPRM1OPRL1L3MBTL1NPC1 | |
| SCHEMBL22570690 | 0.89 | HDAC6 (0.49) | HDAC6OPRM1OPRL1L3MBTL1NPC1 | |
| SCHEMBL20640208 | 0.89 | HDAC6 (0.49) | HDAC6OPRM1OPRL1L3MBTL1NPC1 | |
| SCHEMBL22823349 | 0.83 | OPRM1 (0.66) | OPRM1OPRL1 | |
| SCHEMBL20653795 | 0.79 | HDAC6 (0.52) | HDAC6OPRM1OPRL1L3MBTL1NPC1 | |
| SCHEMBL20640259 | 0.79 | OPRM1 (0.62) | HDAC6OPRM1OPRL1 | |
| SCHEMBL22556052 | 0.76 | OPRM1 (0.58) | OPRM1OPRL1 | |
| SCHEMBL22570694 | 0.76 | OPRM1 (0.49) | HDAC6OPRM1OPRL1L3MBTL1 | |
| SCHEMBL20640206 | 0.75 | HDAC6 (0.49) | HDAC6L3MBTL1NPC1RAB9A | |
| SCHEMBL26649076 | 0.74 | HTT (0.50) | HDAC6L3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200331864-A1 | 1,3-DIAZA-SPIRO-[3.4]-OCTANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2020-10-22 | — | — | US | disclosed |
| US-10738015-B2 | 1,3-diaza-spiro-[3.4]-octane derivatives | Grünenthal GmbH (DE) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738015-B2 | 1,3-diaza-spiro-[3.4]-octane derivatives | OPRK1, OPRD1, OPRL1 | HDAC6 493/4885OPRM1 5/4885OPRL1 3/4885 |
| US-20200331864-A1 | 1,3-DIAZA-SPIRO-[3.4]-OCTANE DERIVATIVES | OPRK1, OPRD1, OPRL1 | HDAC6 493/4885OPRM1 5/4885OPRL1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.